Alliqua BioMedical, Inc. (ALQA)
(Delayed Data from NSDQ)
$2.69 USD
+0.25 (10.11%)
Updated May 3, 2019 04:13 PM ET
After-Market: $2.69 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.69 USD
+0.25 (10.11%)
Updated May 3, 2019 04:13 PM ET
After-Market: $2.69 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
What's in the Cards for Ionis (IONS) this Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report first-quarter 2017 results on May 9. Last quarter, the company recorded a positive earnings surprise of 265%. Let's see how things are shaping up for this announcement.
Orexigen Posts Wider-than-Expected Loss in Q4; Sales Up Y/Y
by Zacks Equity Research
Orexigen Therapeutics, Inc.???s (OREX) loss of $2.67 per share in the fourth quarter of 2016, significantly wider than the both Zacks Consensus Estimate of a loss of 54 cents and the year-ago loss of $1.20.
Ultragenyx's Seizure Candidate UX007 Fails in Phase II Study
by Zacks Equity Research
Ultragenyx Pharmaceutical Inc. (RARE) recently announced that its pipeline candidate UX007 (triheptanoin) failed to meet the primary endpoint in a phase II study evaluating it for the treatment of patients with Glut1 DS with seizures.
Zacks.com featured highlights: include Cambrex, Enzo Biochem, Alliqua BioMedical, CubeSmart and Snap-on
by Zacks Equity Research
Zacks.com featured highlights: include Cambrex, Enzo Biochem, Alliqua BioMedical, CubeSmart and Snap-on